Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04544813
Registration number
NCT04544813
Ethics application status
Date submitted
9/09/2020
Date registered
10/09/2020
Date last updated
29/06/2023
Titles & IDs
Public title
A Study of JNJ-77474462 in Healthy Participants
Query!
Scientific title
A Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of JNJ-77474462 in Healthy Participants
Query!
Secondary ID [1]
0
0
77474462ADM1001
Query!
Secondary ID [2]
0
0
CR108771
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-77474462
Treatment: Drugs - Anakinra
Experimental: Cohort A: JNJ-77474462 SC (Wave 1) - Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
Experimental: Cohort B: JNJ-77474462 SC (Wave 1) - Participants will receive single dose of JNJ-77474462 SC.
Experimental: Cohort C: JNJ-77474462 SC (Wave 1) - Participants will receive single dose of JNJ-77474462 SC.
Experimental: Cohort D: JNJ-77474462 SC (Wave 1) - Participants will receive single dose of JNJ-77474462 SC.
Experimental: Cohort E: JNJ-77474462 IV (Wave 1) - Participants will receive single dose of JNJ-77474462 intravenously (IV).
Experimental: Cohort F: JNJ-77474462 SC (Wave 2) - Participants will receive single dose of JNJ-77474462 SC.
Experimental: Cohort G: JNJ-77474462 SC (Wave 2) - Participants will receive single dose of JNJ-77474462 SC.
Experimental: Cohort H: JNJ-77474462 IV (Wave 2) - Participants will receive single dose of JNJ-77474462 IV.
Experimental: Cohort I: JNJ-77474462 IV (Wave 2) - Participants will receive single dose of JNJ-77474462 IV.
Active Comparator: Cohort J: Anakinra SC - Participants will receive a SC injection of anakinra once daily for 3 days.
Treatment: Drugs: JNJ-77474462
Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
Treatment: Drugs: Anakinra
Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Maximum Observed Plasma Concentration (Cmax) of JNJ-77474462
Query!
Assessment method [1]
0
0
Cmax is the maximum observed plasma concentration.
Query!
Timepoint [1]
0
0
Up to Week 12
Query!
Primary outcome [2]
0
0
Area Under the Plasma Concentration Versus Time Curve from Time Zero to Infinity with Extrapolation of the Terminal Phase (AUC[0-infinity]) of JNJ-77474462
Query!
Assessment method [2]
0
0
AUC(0-infinity) is defined as area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of JNJ-77474462.
Query!
Timepoint [2]
0
0
Up to Week 12
Query!
Primary outcome [3]
0
0
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last]) of JNJ-77474462
Query!
Assessment method [3]
0
0
AUC(0-last) is defined as area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of JNJ-77474462.
Query!
Timepoint [3]
0
0
Up to Week 12
Query!
Primary outcome [4]
0
0
Terminal Half-Life (T1/2) of JNJ-77474462
Query!
Assessment method [4]
0
0
T1/2 is defined as the time measured for the plasma concentration to decrease by 1 half of its original concentration.
Query!
Timepoint [4]
0
0
Up to Week 12
Query!
Primary outcome [5]
0
0
Absolute Subcutaneous (SC) Bioavailability (F%)
Query!
Assessment method [5]
0
0
(F%) is defined as absolute SC bioavailability to be calculated using the following equation: AUC(0-infinity) SC/mean AUC(0-infinity) IV * 100 percent (%).
Query!
Timepoint [5]
0
0
Up to Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants with Treatment-emergent Adverse Events (TEAE)
Query!
Assessment method [1]
0
0
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment.
Query!
Timepoint [1]
0
0
Up to Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants with Serious Adverse Events (SAE)
Query!
Assessment method [2]
0
0
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Query!
Timepoint [2]
0
0
Up to Week 12
Query!
Secondary outcome [3]
0
0
Number of Participants with Clinically Significant Changes in Vital Signs
Query!
Assessment method [3]
0
0
Number of participants with clinically significant changes in vital signs (including body temperature, resting [supine] pulse/heart rate, respiratory rate and blood pressure) will be reported.
Query!
Timepoint [3]
0
0
Up to Week 12
Query!
Secondary outcome [4]
0
0
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG)
Query!
Assessment method [4]
0
0
Number of participants with clinically significant changes ECG will be reported.
Query!
Timepoint [4]
0
0
Up to Week 12
Query!
Secondary outcome [5]
0
0
Number of Participants with Clinically Significant Changes in Laboratory Findings
Query!
Assessment method [5]
0
0
Number of participants with clinically significant changes in laboratory findings (that is, hematology, clinical chemistry, urinalysis) will be reported.
Query!
Timepoint [5]
0
0
Up to Week 12
Query!
Secondary outcome [6]
0
0
Number of Participants with Anti-JNJ-77474462 Antibodies
Query!
Assessment method [6]
0
0
Number of participants with anti-drug antibodies to JNJ-77474462 will be reported.
Query!
Timepoint [6]
0
0
Up to Week 12
Query!
Eligibility
Key inclusion criteria
- Otherwise healthy on the basis of physical examination, medical history, vital signs,
and 12 lead electrocardiogram (ECG) performed at screening. Any abnormalities must be
considered not clinically significant and this determination must be recorded in the
participant's source documents and initialed by the investigator
- Otherwise healthy on the basis of clinical laboratory tests performed at screening and
Day 1. If the results of the serum chemistry panel, hematology, or urinalysis are
outside the normal reference ranges, the participant may be included only if the
investigator judges the abnormalities or deviations from normal to be not clinically
significant or to be appropriate and reasonable for the population under study. This
determination must be recorded in the participant's source documents and initialed by
the investigator
- A woman of childbearing potential must have a negative highly sensitive serum
beta-human chorionic gonadotropin (beta hCG) at screening and a negative urine
pregnancy test on Day -1
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
reproduction during the study and for a period of 90 days post study intervention
administration
- A male participant must agree not to donate sperm for the purpose of reproduction
during the study and for a minimum of 90 days after receiving the last dose of study
intervention
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- History of any clinically significant medical illness or medical disorders the
investigator considers should exclude the participant, including (but not limited to),
neuromuscular, hematological disease, immune deficiency state, respiratory disease,
hepatic or gastrointestinal disease, neurological or psychiatric disease,
ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or
dermatological disease
- Has a history of malignancy before screening. Exceptions are squamous and basal cell
carcinomas of the skin, carcinoma in situ of the cervix, or a malignancy which is
considered cured with minimal risk of recurrence
- Has or has had a serious infection (example: sepsis, pneumonia, or pyelonephritis), or
have been hospitalized or received intravenous (IV) antibiotics for a serious
infection during the 4 months prior to the screening visit
- Is currently enrolled in an investigational study or has received an investigational
intervention (including investigational vaccines or devices) 5 half-lives or 8 weeks
prior to screening (whichever is longer)
- Has received prescription medications within 2 weeks prior to first study intervention
administration
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/05/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
78
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Nucleus Network, Q-Pharm Pty Ltd - Herston
Query!
Recruitment postcode(s) [1]
0
0
4006 - Herston
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 after single
subcutaneous (SC) or intravenous (IV) administrations and the effect of formulation
concentrations on PK of JNJ-77474462 in healthy participants.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04544813
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04544813
Download to PDF